# Trinucleotide repeat disorder

**Trinucleotide repeat disorders** are a set of genetic disorders caused by trinucleotide repeat expansion, a kind of mutation in which repeats of three nucleotides (trinucleotide repeats) increase in copy numbers until they cross a threshold above which they become unstable. Depending on where it is located, the unstable trinucleotide repeat may cause defects in a protein encoded by a gene, change the regulation of gene expression, produce a toxic RNA, or lead to chromosome instability. In general, the larger the expansion the faster the onset of disease, and the more severe the disease becomes. [1]

# Trinucleotide repeat disorder

Other Trinucleotide repeat
names expansion disorders,
Triplet repeat expansion
disorders or Codon
reiteration disorders

Trinucleotide repeats are a subset of a larger class of unstable <u>microsatellite</u> repeats that occur throughout all genomes.

The first trinucleotide repeat disease to be identified was fragile X syndrome, which has since been mapped to the long arm of the X chromosome. Patients carry from 230 to 4000 CGG repeats in the gene that causes fragile X syndrome, while unaffected individuals have up to 50 repeats and carriers of the disease have 60 to 230 repeats. The chromosomal instability resulting from this trinucleotide expansion presents clinically as intellectual disability, distinctive facial features, and macroorchidism in males. The second DNA-triplet repeat disease, fragile X-E syndrome, was also identified on the X chromosome, but was found to be the result of an expanded CCG repeat. The discovery that trinucleotide repeats could expand during intergenerational transmission and could cause disease was the first evidence that not all disease-causing mutations are stably transmitted from parent to offspring. [1]

There are several known categories of trinucleotide repeat disorder. Category I includes <u>Huntington's disease</u> (HD) and the <u>spinocerebellar ataxias</u>. These are caused by a CAG repeat expansion in protein-coding portions, or <u>exons</u>, of specific genes. Category II expansions are also found in exons, and tend to be more <u>phenotypically</u> diverse with heterogeneous expansions that are generally small in magnitude. Category III includes fragile X syndrome, <u>myotonic dystrophy</u>, two of the spinocerebellar ataxias, juvenile <u>myoclonic epilepsy</u>, and <u>Friedreich's ataxia</u>. These diseases are characterized by typically much larger repeat expansions than the first two groups, and the repeats are located in <u>introns</u> rather than exons.

## **Contents**

#### **Types**

Polyglutamine (PolyQ) diseases Non-polyglutamine diseases

#### **Symptoms**

#### **Genetics**

Non-trinucleotide expansions

#### Mechanism

See also

References
External links

# **Types**

Some of the problems in trinucleotide repeat syndromes result from causing alterations in the <u>coding</u> region of the protein, while others are caused by altered <u>gene regulation</u>.<sup>[1]</sup> In over half of these disorders, the repeated trinucleotide, or <u>codon</u>, is CAG. In a coding region, CAG codes for <u>glutamine</u> (Q), so CAG repeats result in a <u>polyglutamine tract</u>. These diseases are commonly referred to as **polyglutamine** (or polyQ) diseases. The repeated codons in the remaining disorders do not code for glutamine, and these are classified as non-polyglutamine diseases.

#### Polyglutamine (PolyQ) diseases

Туре	Gene	Normal PolyQ repeats	Pathogenic PolyQ repeats
DRPLA (Dentatorubropallidoluysian atrophy)	ATN1 or DRPLA	6 - 35	49 - 88
HD (Huntington's disease)	HTT	6 - 35	36 - 250
SBMA (Spinal and bulbar muscular atrophy)	AR	9 - 36	38 - 62
SCA1 (Spinocerebellar ataxia Type 1)	ATXN1	6 - 35	49 - 88
SCA2 (Spinocerebellar ataxia Type 2)	ATXN2	14 - 32	33 - 77
SCA3 (Spinocerebellar ataxia Type 3 or Machado- Joseph disease)	ATXN3	12 - 40	55 - 86
SCA6 (Spinocerebellar ataxia Type 6)	CACNA1A	4 - 18	21 - 30
SCA7 (Spinocerebellar ataxia Type 7)	ATXN7	7 - 17	38 - 120
SCA17 (Spinocerebellar ataxia Type 17)	ТВР	25 - 42	47 - 63

# Non-polyglutamine diseases

Туре	Gene	Codon	Normal	Pathogenic	Mechanism <sup>[1]</sup>
FRAXA ( <u>Fragile X syndrome</u> )	FMR1	<b>CGG</b> (5' UTR)	6 - 53	230+	abnormal methylation
FXTAS (Fragile X-associated tremor/ataxia syndrome)	FMR1	<b>CGG</b> (5' UTR)	6 - 53	55-200	increased expression, and a novel polyglycine product <sup>[3]</sup>
FRAXE (Fragile XE mental retardation)	AFF2	<b>CCG</b> (5' UTR)	6 - 35	200+	abnormal methylation
FRDA (Friedreich's ataxia)	FXN	GAA (Intron)	7 - 34	100+	impaired transcription
DM1 (Myotonic dystrophy Type 1)	DMPK	CTG (3' UTR)	5 - 34	50+	RNA-based; unbalanced DMPK/ZNF9 expression levels
SCA8 (Spinocerebellar ataxia Type 8)	SCA8	CTG (RNA)	16 - 37	110 - 250	? RNA
SCA12 ( <u>Spinocerebellar ataxia</u> Type 12)	PPP2R2B	nnn (5' UTR)	7 - 28	66 - 78	

# **Symptoms**

A common symptom of polyQ diseases is the progressive degeneration of nerve cells, usually affecting people later in life. Although these diseases share the same repeated codon (CAG) and some symptoms, the repeats are found in different, unrelated genes. In all cases, the expanded CAG repeats are translated into an uninterrupted sequence of glutamine residues, forming a polyQ tract, and the accumulation of polyQ proteins damages key cellular functions such as the ubiquitin-proteasome system. However different polyQ-containing proteins damage different subsets of neurons, leading to different symptoms. [4] As of 2017, ten neurological and neuromuscular disorders were known to be caused by an increased number of CAG repeats.<sup>[5]</sup>

The **non-PolyQ diseases** do not share any specific symptoms and are unlike the PolyQ diseases. In some of these diseases, such as Fragile X syndrome, the pathology is caused by lack of the normal function of the protein encoded by the affected gene. In others, such as Monotonic Dystrophy Type 1, the pathology is caused by a change in protein expression or function mediated through changes in the messenger RNA produced by the expression of the affected gene.<sup>[1]</sup> In yet others, the pathology is caused by toxic assemblies of RNA in the nuclei of cells.<sup>[6]</sup>

# **Genetics**

Trinucleotide repeat disorders generally show genetic anticipation: their severity increases with disease status, depends on the number of CAG repeats in each successive generation that inherits them. This is likely explained by the addition of CAG repeats in the affected gene as the gene is transmitted from parent to child. For example, Huntington's disease occurs when there are more than 35 CAG repeats on the gene coding for the protein HTT. A parent with 35 repeats would be considered normal and would not exhibit any symptoms of the disease.<sup>[7]</sup> However, that parent's offspring would be at an

Classification of the trinucleotide repeat, and resulting Huntington's disease<sup>[7]</sup>

Repeat count	Classification	Disease status
<28	Normal	Unaffected
28–35	Intermediate	Unaffected
36–40	Reduced-penetrance	May be affected
>40	Full-penetrance	Affected

increased risk of developing Huntington's compared to the general population, as it would take only the addition of one more CAG codon to cause the production of mHTT (mutant HTT), the protein responsible for disease.

Huntington's very rarely occurs spontaneously; it is almost always the result of inheriting the defective gene from an affected parent. However, sporadic cases of Huntington's in individuals who have no history of the disease in their families do occur. Among these sporadic cases, there is a higher frequency of individuals with a parent who already has a significant number of CAG repeats in their *HTT* gene, especially those whose repeats approach the number (36) required for the disease to manifest. Each successive generation in a Huntington's-affected family may add additional CAG repeats, and the higher the number of repeats, the more severe the disease and the earlier its onset. [7] As a result, families that have suffered from Huntington's for many generations show an earlier age of disease onset and faster disease progression. [7]

#### Non-trinucleotide expansions

The majority of diseases caused by expansions of simple DNA repeats involve trinucleotide repeats, but tetra-, penta- and dodecanucleotide repeat expansions are also known that cause disease. For any specific hereditary disorder, only one repeat expands in a particular gene.<sup>[8]</sup>

## **Mechanism**

Triplet expansion is caused by *slippage* during <u>DNA replication</u> or during <u>DNA repair</u> synthesis.<sup>[9]</sup> Because the tandem repeats have identical sequence to one another, <u>base pairing</u> between two DNA strands can take place at multiple points along the sequence. This may lead to the formation of 'loop out' structures during DNA replication or DNA repair synthesis.<sup>[10]</sup> This may lead to repeated copying of the repeated sequence, expanding the number of repeats. Additional mechanisms involving hybrid RNA:DNA intermediates have been proposed.<sup>[11][12]</sup>

### See also

- C9orf72
- RAN translation

## References

- 1. Orr HT, Zoghbi HY (2007). "Trinucleotide repeat disorders". *Annual Review of Neuroscience*. **30** (1): 575–621. doi:10.1146/annurev.neuro.29.051605.113042 (https://doi.org/10.1146%2Fannurev.neuro.2 9.051605.113042). PMID 17417937 (https://pubmed.ncbi.nlm.nih.gov/17417937).
- 2. "Fragile XE syndrome" (http://rarediseases.info.nih.gov/GARD/Condition/2378/Fragile\_XE\_syndrome.aspx). Genetic and Rare Diseases Information Center (GARD). Retrieved 14 September 2012.
- 3. Gao FB, Richter JD (January 2017). "Microsatellite Expansion Diseases: Repeat Toxicity Found in Translation". *Neuron.* **93** (2): 249–251. doi:10.1016/j.neuron.2017.01.001 (https://doi.org/10.1016%2 Fj.neuron.2017.01.001). PMID 28103472 (https://pubmed.ncbi.nlm.nih.gov/28103472).

- 4. Fan, Hueng-Chuen; Ho, Li-Ing; Chi, Ching-Shiang; Chen, Shyi-Jou; Peng, Giia-Sheun; Chan, Tzu-Min; Lin, Shinn-Zong; Harn, Horng-Jyh (May 2014). "Polyglutamine (PolyQ) Diseases: Genetics to Treatments". Cell Transplantation. 23 (4–5): 441–458. doi:10.3727/096368914X678454 (https://doi.org/10.3727%2F096368914X678454). ISSN 0963-6897 (https://www.worldcat.org/issn/0963-6897). PMID 24816443 (https://pubmed.ncbi.nlm.nih.gov/24816443).
- Adegbuyiro A, Sedighi F, Pilkington AW, Groover S, Legleiter J (March 2017). "Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727916). Biochemistry. 56 (9): 1199–1217. doi:10.1021/acs.biochem.6b00936 (https://doi.org/10.1021%2Facs.biochem.6b00936). PMC 5727916 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727916). PMID 28170216 (https://pubmed.ncbi.nlm.nih.gov/28170216).
- Brangwynne, Clifford P.; Sanders, David W. (June 2017). "Neurodegenerative disease: RNA repeats put a freeze on cells". *Nature*. 546 (7657): 215–216. <u>Bibcode</u>:2017Natur.546..215S (https://ui.adsabs.harvard.edu/abs/2017Natur.546..215S). doi:10.1038/nature22503 (https://doi.org/10.1038%2Fnature22503). <u>ISSN</u> 1476-4687 (https://www.worldcat.org/issn/1476-4687). <u>PMID</u> 28562583 (https://pubm.ed.ncbi.nlm.nih.gov/28562583).
- 7. Walker FO (January 2007). "Huntington's disease". *Lancet*. **369** (9557): 218–28. <u>doi:10.1016/S0140-6736(07)60111-1</u> (https://doi.org/10.1016%2FS0140-6736%2807%2960111-1). <u>PMID</u> 17240289 (https://pubmed.ncbi.nlm.nih.gov/17240289).
- Mirkin, Sergei M. (June 2007). "Expandable DNA repeats and human disease". *Nature*. 447 (7147): 932–940. Bibcode:2007Natur.447..932M (https://ui.adsabs.harvard.edu/abs/2007Natur.447..932M). doi:10.1038/nature05977 (https://doi.org/10.1038%2Fnature05977). ISSN 0028-0836 (https://www.worldcat.org/issn/0028-0836). PMID 17581576 (https://pubmed.ncbi.nlm.nih.gov/17581576).
- 9. Usdin K, House NC, Freudenreich CH (2015). "Repeat instability during DNA repair: Insights from model systems" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454471). Critical Reviews in Biochemistry and Molecular Biology. 50 (2): 142–67. doi:10.3109/10409238.2014.999192 (https://doi.org/10.3109%2F10409238.2014.999192). PMC 4454471 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4454471). PMID 25608779 (https://pubmed.ncbi.nlm.nih.gov/25608779).
- Petruska J, Hartenstine MJ, Goodman MF (February 1998). "Analysis of strand slippage in DNA polymerase expansions of CAG/CTG triplet repeats associated with neurodegenerative disease". The Journal of Biological Chemistry. 273 (9): 5204–10. doi:10.1074/jbc.273.9.5204 (https://doi.org/10.1074%2Fjbc.273.9.5204). PMID 9478975 (https://pubmed.ncbi.nlm.nih.gov/9478975).
- 11. McIvor EI, Polak U, Napierala M (2010). "New insights into repeat instability: role of RNA•DNA hybrids" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073251). RNA Biology. 7 (5): 551–8. doi:10.4161/rna.7.5.12745 (https://doi.org/10.4161%2Frna.7.5.12745). PMC 3073251 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073251). PMID 20729633 (https://pubmed.ncbi.nlm.nih.gov/20729633).
- 12. Salinas-Rios V, Belotserkovskii BP, Hanawalt PC (September 2011). "DNA slip-outs cause RNA polymerase II arrest in vitro: potential implications for genetic instability" (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177194). Nucleic Acids Research. 39 (17): 7444–54. doi:10.1093/nar/gkr429 (https://doi.org/10.1093%2Fnar%2Fgkr429). PMC 3177194 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177194). PMID 21666257 (https://pubmed.ncbi.nlm.nih.gov/21666257).

# **External links**

- Trinucleotide+Repeat+Expansion (https://meshb.nlm.nih.gov/record/ui?name=Trinucleotide%20Repe at%20Expansion) at the US National Library of Medicine Medical Subject Headings (MeSH)
- GeneReviews/NCBI/NIH/UW entry on DRPLA (https://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=drpla)
- National Institute of Neurological Disorders and Stroke (http://www.ninds.nih.gov/disorders/disorder\_index.htm)
- Genetics Home Reference (http://ghr.nlm.nih.gov/)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Trinucleotide repeat disorder&oldid=945699887"

This page was last edited on 15 March 2020, at 16:53 (UTC).

Text is available under the <u>Creative Commons Attribution-ShareAlike License</u>; additional terms may apply. By using this site, you agree to the <u>Terms of Use</u> and <u>Privacy Policy</u>. Wikipedia® is a registered trademark of the <u>Wikimedia Foundation</u>, Inc., a non-profit organization.